GlassScriptPhysician profile
John R Barnes
NPI 1205865680
$1,645.78
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $362 · 2021: $369 · 2022: $488 · 2024: $18.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $410.01 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $193.39 | 2019-2022 | |
| Amgen INC. | $166.07 | 2019-2020 | |
| Glaxosmithkline, LLC. | $95.68 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $83.62 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.59 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.39 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $69.94 | 2019-2022 | |
| Abbott Laboratories | $50.87 | 2021-2022 | |
| Horizon Therapeutics Plc | $48.06 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $44.22 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $42.47 | 2020-2022 | |
| Eisai INC. | $40.57 | 2020 | |
| Lilly USA, LLC | $37.07 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.02 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $27.57 | 2019-2020 | |
| Pfizer INC. | $23.92 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $19.90 | 2020 | |
| Siemens Medical Solutions USA, INC. | $18.93 | 2024 | Atellica Im 1300 Analyzer |
| Nestle Healthcare Nutrition INC. | $16.55 | 2021 | |
| Esperion Therapeutics, INC. | $15.86 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $14.87 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.49 | 2019 | |
| Idorsia Pharmaceuticals US INC | $12.61 | 2022 | |
| Boston Scientific Corporation | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.